Exploring a ‘Rescue’ Strategy for Your Oncology Clinical Trial?
Although not formally defined within the industry, the term ‘rescue’ is commonly linked with clinical trials where enrollment is falling…
Effectively Integrating a Regionally Specialized CRO Team into Your Existing US/Global Study Framework
The expansion of an oncology study to ex-US areas, such as Canada, brings many advantages, including faster patient accrual and…
Navigating Canadian Regulations for Oncology Clinical Research – Part I
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part I Senior executives from oncology drug developers looking to…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
Continued from ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiation part 1 Nathan Currier, PhD, is Scimega's…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
Nathan Currier, PhD, is Scimega's Director of Oncology Strategy and Alliances. He brings a wealth of knowledge and excellent insight…
Accelerate Start-up for Oncology Clinical Trials through Centralized Ethics Review
The strong demand for optimised oncology clinical trials has led Canadian provinces to implement centralised ethics review. Granted many of these provincial ethics…